Literatur
- 1
Agus D B. et al .
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Cancer Cell.
2002;
2
127-137
- 2
Apperley J F. et al .
Response to imatinib mesylate in patients with chronic myeloproliferative diseases
with rearrangements of the platelet-derived growth factor receptor beta.
N Engl J Med.
2002;
347
481-487
- 3
Arteaga C L.
Selecting the right patient for tumor therapy.
Nat Med.
2004;
10
577-578
- 4
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D.
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature
with kinase inhibitors.
J Clin Invest.
2003;
111
1287-1295
- 5
Ciardiello F. et al .
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells
by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase
inhibitor.
Clin Cancer Res.
2000;
6
2053-2063
- 6
Cunningham D. et al .
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic
colorectal cancer.
N Engl J Med.
2004;
351
337-345
- 7
Demetri G D. et al .
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med.
2002;
347
472-480
- 8
Griffin R J. et al .
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast,
and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation
response.
Cancer Res.
2002;
62
1702-1706
- 9
Herbst R S, Shin D M.
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors:
a new paradigm for cancer therapy.
Cancer.
2002;
94
1593-1611
- 10
Hurwitz H. et al .
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer.
N Engl J Med.
2004;
350
2335-2342
- 11
Kantarjian H M. et al .
Long-Term Survival Benefit and Improved Complete Cytogenetic and Molecular Response
Rates with Imatinib Mesylate in Philadelphia Chromosome-Positive, Chronic-Phase Chronic
Myeloid Leukemia after Failure of Interferon-{alpha}.
Blood.
2004;
15
15
- 12
Ross D M, Hughes T P.
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?.
Br J Cancer.
2004;
90
12-19
- 13
Slamon D J. et al .
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2.
N Engl J Med.
2001;
344
783-792
- 14
Terre C. et al .
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative
cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Leukemia.
2004;
18
1340-1346
- 15
von Bubnoff N, Schneller F, Peschel C, Duyster J.
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive
leukaemia to STI571: a prospective study.
Lancet.
2002;
359
487-491
- 16
Wood J M. et al .
PTK787/ZK 222 584, a novel and potent inhibitor of vascular endothelial growth factor
receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses
and tumor growth after oral administration.
Cancer Res.
2000;
60
2178-2189
- 17
Xiong H Q. et al .
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in
combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II
Trial.
J Clin Oncol.
2004;
22
2610-2616
Dr. med. Christian Grimm
Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg
Hugstetter Straße 55
79106 Freiburg
Phone: 0761/2703401
Fax: 0761/2703762
Email: grimm@med1.ukl.uni-freiburg.de
Email: christian.grimm@email.de
